What Merck Sees in This Biotech Could Change the Game

U.S. stocks were mixed as early losses from fading Fed rate cut hopes were partially offset by dip buying in AI stocks like Nvidia and Palantir.

Walmart (NYSE: WMT) is trimming its once generous Thanksgiving bundle and doing it quietly.

The retailer wants a cleaner, tighter approach as shoppers become careful with every dollar.

The move focuses on simple offers that are easier to manage and easier to understand. You can already feel how different this season looks compared to the wild holiday rush of past years.

Shoppers Are Flipping the Script

Middle and lower-income households are trading down, switching brands, and skipping extras.

Walmart sees these changes and is shifting its holiday strategy before the rest of the market wakes up.

Tariffs and economic pressure keep pushing people toward essential buys instead of big seasonal splurges.

You might notice how fast those patterns force retailers to rethink every part of their holiday plans.

Value Wars Start Now

Walmart wants smoother inventory, easier staffing, and fewer supply chain headaches as costs keep building.

A tighter assortment gives the company the control it needs when the season gets loud.

Other stores will probably pull back as well, but Walmart’s size makes the shift echo across the whole retail world.

A season built on essentials might even shape how you approach holiday shopping this year.

Walmart just grabbed the holiday script, tossed the noise aside, and walked into December ready to show you how a real reset looks.

JPMorgan (NYSE: JPM) secured paid data-access deals with Plaid, Yodlee, Morningstar, and Akoya, covering nearly every major third-party app in the country.

The bank now owns the doorway that those apps need every time someone links an account.

A setup like this gives JPMorgan tighter control over nonstop data traffic. Somewhere in that shift, you can see the early outline of a brand-new business model forming.

Free Data Days Run Out

Fintech apps spent years tapping bank systems without covering the costs behind the scenes.

JPMorgan changed the tone overnight by setting a structure where the heaviest users finally share the load.

Paid access keeps the system cleaner as the volume of connections keeps rising.

Some apps will need to rethink their budgets, especially if you depend on them for daily money checks.

A Gatekeeper Steps Into the Light

JPMorgan now earns from the same digital rails it spent years maintaining quietly in the background.

A more organized setup means fewer system headaches and more upside for long-term expansion.

Smaller apps may feel pressure, yet the biggest names will adapt because staying plugged in is part of survival.

When the dust settles, you might watch JPMorgan become the company that decides how open banking actually works.

JPMorgan basically put up a toll sign and left you watching fintech pay the cover charge.

How many of your stocks are truly positioned to break out this year?

A new screening of thousands of companies just narrowed the field to 5 stocks with strong potential to gain 100 percent or more.

The latest special report reveals all five names at no cost.

Past editions highlighted gains of 175%, 498% and even 673%.

Download it before access closes at midnight.

Merck (NYSE: MRK) snapped up Cidara in a $9.2 billion deal that shocked a sleepy pharma week.

The company wanted more than a single drug and reached for a whole platform instead.

The company wants to generate fresh momentum before its older drugs start to lose steam. You can feel how urgent the shift is as the company tries to stack future wins early.

Science With A Heavy Punch

Cidara brings a nearly ready antiviral program that aligns perfectly with Merck’s long-term strategy.

The pickup hands Merck tools that can support revenue once the older hits slow down.

Health agencies keep asking for longer-acting protection and stronger global readiness. You might notice how those demands create a giant lane for companies willing to go bold right now.

Big Pharma Playing Street Rules Now

Merck wants assets close to market because waiting years for risky projects no longer feels smart.

A move like this puts pressure on slow-moving rivals who had hoped the old pace would still work.

The company is building a cleaner handoff from aging products to a fresher lineup that sparks new stories.

A louder antiviral engine could shape the next decade in ways you eventually see across every health headline.

Merck just punched the gas and treated the future like a door that needed kicking.

👉 Click here to get our closing report to your cell for free!

Cidara Thera [CDTX] $217.71 (+105.41%)

Cidara surged after Merck agreed to acquire it for $9.2 billion, betting on its novel influenza prevention drug CD388 with FDA Breakthrough Therapy Designation.

Cycurion Inc [CYCU] $6.32 (+51.20%)

Cycurion popped after reporting strong Q3 results, highlighting an $80 million contract backlog, new government deals, and a bullish 2026 revenue forecast powered by AI-driven cybersecurity.

Legence Corp. [LGN] $40.41 (+21.28%)

Legence rose after a solid Q3 earnings beat and a 26% revenue jump, supported by record backlog and robust demand from data centers and healthcare sectors.

TSS Inc [TSSI] $8.64 (-43.34%)

TSS fell after Q3 revenue plunged 40% and EBITDA dropped 66%, as AI-related rack integration volumes underperformed expectations.

StubHub Holdings Inc [STUB] $14.87 (-20.99%)

StubHub tumbled after withholding current-quarter guidance in its first earnings report as a public company, triggering investor uncertainty.

AIRO Group Holdings Inc [AIRO] $10.10 (-20.78%)

AIRO declined after Q3 revenue dropped 73% YoY due to shipment delays in its drone division, raising concerns despite a strong Q4 pipeline.

When he started trading 30 years ago, he made every mistake possible.

Then he found a way to simplify it — using one indicator that shows him exactly when to buy and sell.

Now, he’s sharing that same system with everyday investors, free of charge.

No charts to memorize. No strategies to decode.

Just a clear signal that’s helped guide his trades for decades and it’s flashing again right now.

See how this tool can help you stop guessing and start acting with confidence.

[Access the free indicator today]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.